Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 44Brain Neoplasms 22Carcinoma, Renal Cell 10Neoplasm Metastasis 9Sarcoma 7Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Uveal Melanoma 5Gastrointestinal Neoplasms 4Small Cell Lung Carcinoma 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Spinal Cord Compression 2Skin Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Radiation Injuries 1

Interventions

atezolizumab 2spartalizumab 1pembrolizumab 1entrectinib 1cobimetinib 1Vemurafenib 1Taxes 1Radiosurgery 1Pemetrexed 1Paclitaxel 1Nivolumab 1HuMax-IL8 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Radiosurgery × Dermatologic × Clear all
NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Dermatologic

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡